Abstract: This document relates to materials and methods for controlling ligand gated ion channel (LGIC) activity. For example, modified LGICs including at least one LGIC subunit having a modified ligand binding domain (LBD) and/or a modified ion pore domain (IPD) are provided. Also provided are exogenous LGIC ligands that can bind to and activate the modified LGIC, as well as methods of modulating ion transport across the membrane of a cell of a mammal, methods of modulating the excitability of a cell in a mammal, and methods of treating a mammal having a channelopathy.
Type:
Grant
Filed:
August 19, 2019
Date of Patent:
April 20, 2021
Assignee:
Howard Hughes Medical Institute
Inventors:
Scott Sternson, Peter Lee, Christopher Magnus
Abstract: The human LIV21 protein as a diagnostic and prognostic marker for various cancers and neurodegenerative diseases is provided. Methods for diagnosing and/or prognosing cancer utilizing the LIV21 protein and various derivatives and peptide fragments of the LIV21 protein are also provided.
Abstract: The invention refers to medicine and pharmacology, namely, to biologically active peptides, which modulate purinergic signaling. For that, the peptide with the following amino acid sequence is proposed: Gly1-Tyr2-Cys3-Ala4-Thr5-Lys6-Gly7-Ile8-Lys9-Cys10- Asn11-Asp12-Ile13-His14-Cys15-Cys16-Ser17-Gly18-Leu19- Lys20-Cys21-Asp22-Ser23-Lys24-Arg25-Lys26-Val27-Cys28- Val29-Lys30-Gly31, or a sequence with at least 90% homology hereto. Peptides in the invention can be used for prevention and treatment of diseases mediated by purinergic receptors. The peptides can be used for development of new drugs on their basis, for example, analgesics, as well for investigation of mechanisms of pain occurrence, for identification and testing of new modulators of P2X3 receptors. The peptides in the invention can be produced using chemical synthesis or biotechnologically using the nucleotide sequence of the corresponding gene.
Abstract: In certain aspects, the present invention provides compositions and methods for inducing utrophin expression in muscle with an ActRIIB protein as therapy for muscular dystrophy. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand.
Abstract: The present invention relates to a novel protein formulation. In particular, the invention relates to a liquid pharmaceutical composition of an antibody directed to Interleukin-6 receptor, a method of manufacturing the composition, a kit including the composition, a package including the composition and to methods of treatment using the composition and/or package.
Abstract: The present invention relates to antibodies having activity against a vascular endothelial growth factor (VEGF), and methods of making and using such antibodies.
Type:
Grant
Filed:
August 22, 2017
Date of Patent:
February 16, 2021
Assignee:
MEDIMMUNE LIMITED
Inventors:
Ching Ching Leow, Nazzareno Dimasi, Karen Coffman, Ping Tsui, Changshou Gao, Mario A. Cepeda, Adrian Schwartz Mittelman
Abstract: Disclosed herein is a method for identifying TREM-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1's ligand and reduce TREM-1 activity may be suitable for use as medicaments.
Type:
Grant
Filed:
October 25, 2018
Date of Patent:
February 2, 2021
Assignee:
NOVO NORDISK A/S
Inventors:
Vibeke Westphal Stennicke, Christine Brender Read, Joseph Leon Kuijper, Xiaoting Tang, Mark Heipel, Siv Annegrethe Hjorth
Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.
Abstract: Methods of treating acute thyroid eye disease (TED) by administering a inhibitor, e.g., a VEGF-A inhibitor, e.g., an anti-VEGF antibody, optionally in combination with hyaluronidase, by periorbital or intraorbital injection. Also compositions comprising a VEGF inhibitor and hyaluronidase.
Type:
Grant
Filed:
June 8, 2017
Date of Patent:
February 2, 2021
Assignees:
Massachusetts Eye and Ear Infirmary, The Schepens Eye Research Institute, Inc.
Inventors:
N. Grace Lee, Leo Kim, Patricia A. D'Amore, James A. Stefater
Abstract: The present disclosure relates to, among other things, compounds and methods for treating neuropathic pain, ocular pain, ocular inflammation, and/or dry eye and methods of detecting mutations in specific G-protein coupled receptors, such as missense mutations, and determining the extent to which these mutations alter the pharmacological response of the G-protein coupled receptor.
Type:
Grant
Filed:
November 9, 2016
Date of Patent:
January 26, 2021
Assignees:
Tufts Medical Center, Trustees of Tufts College
Inventors:
Alan S. Kopin, Krishna Kumar, Jamie Raudensky Doyle
Abstract: The present invention provides the use of neuregulin protein for the preparation of medication for preventing, treating or delaying heart failure in humans and methods for preventing, treating or delaying heart failure in humans using said medication.
Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
Abstract: The present invention relates to amino acid sequences and polypeptides binding to the P2X7 receptor. In particular, the present invention relates to improved heavy-chain immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVD's”) binding to the P2X7 receptor, as well as to proteins, polypeptides and other constructs, compounds, molecules or 5 chemical entities that comprise such ISVD's.
Abstract: The present invention discloses an antibody specifically binding to a human endothelin receptor and uses thereof, where the antibody can inhibit the functions of the human endothelin receptor. The present invention includes the preparation, cloning, expression, and characterization of the antibody. The present invention can be used to effectively treat pulmonary arterial hypertension, a disease associated with pulmonary arterial hypertension, and a reproductive organ cancer in a human.
Type:
Grant
Filed:
August 12, 2019
Date of Patent:
December 22, 2020
Assignee:
GMAX BIOPHARM LLC
Inventors:
Cheng Zhang, Hua Zhang, Xiaofeng Wang, Chenjiang Yao, Yan Jiang, Min Wang, Xinxin Shi, Hao Pan, Shuqian Jing
Abstract: Provided herein are antigen binding polypeptides and complexes thereof having agonist activity. Also provided are methods for screening for complexes or polypeptides having agonist activity, enhancing the agonist activity of a polypeptide, and for agonizing a cell surface receptor using the complexes and polypeptide described herein.
Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
Abstract: The disclosure provides methods and compositions for inhibiting pain by administering a GPR160 antagonist to a subject in need thereof. Also provided are methods of using GPR160 antagonists in combination with other pain therapies.
Type:
Grant
Filed:
July 15, 2016
Date of Patent:
December 1, 2020
Assignee:
Saint Louis University
Inventors:
Daniela Salvemini, Gina L. C. Yosten, Willis K. Samson
Abstract: The present disclosure provides antibodies and antigen-binding fragments capable of binding PAR2. In some embodiments, the anti-PAR2 antibodies or antigen-binding fragments thereof bind PAR2 in a pH-dependent manner. The disclosure further provides methods for making and using the antibodies and antigen-binding fragments.
Type:
Grant
Filed:
March 16, 2018
Date of Patent:
November 17, 2020
Assignee:
MedImmune Limited
Inventors:
Claire Dobson, Richard Williams, Ian Gurrell, Sadhana Podichetty, David Fairman, Peter Thornton, Philip Newton
Abstract: The present invention relates to bispecific antibodies having activity against a vascular endothelial growth factor (VEGF) and an angiopoietin (ANG), and methods of making and using such bispecific antibodies.
Type:
Grant
Filed:
August 22, 2017
Date of Patent:
November 17, 2020
Assignee:
MEDIMMUNE LIMITED
Inventors:
Ching Ching Leow, Nazzareno Dimasi, Karen Coffman, Ryan Fleming, Ping Tsui, Changshou Gao, Mario A. Cepeda, Adrian Schwartz Mittelman
Abstract: A method of producing synergistic and enhanced efficacy in treating a disease in a subject includes providing an antibody, the antibody being a classic antibody or a modified biologic molecule that blocks a first target in the subject; providing a drug, the drug being a small molecule agent that blocks the first target or a second target in the subject; connecting the antibody and the drug with a linker to form an Antibody-Drug Synergism (ADS) compound; and treating the disease with the ADS compound. The linker is hydrolyzed in the subject over a certain time so that both the antibody and the drug exert their functions simultaneously, and the ADS compound confers better efficacy than either the antibody or the drug alone due to a synergism of the ADS compound.